無料プレビュー

Olema Pharmaceuticals, Inc. (OLMA) · NASDAQ Global Select

プロフィール

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for breast cancer and other hormone-driven cancers. The company's lead product candidate, palazestrant, is an oral small molecule functioning as both a complete estrogen receptor antagonist and selective estrogen receptor degrader, currently in pivotal Phase 3 trials for ER-positive/HER2-negative metastatic breast cancer as monotherapy and in combination with CDK4/6 inhibitors. Olema's second product candidate, OP-3136, is a KAT6 inhibitor in early-stage clinical development for breast and other s

主要指標

株価: $7.82 (-1.51%)
時価総額: 7億ドル
PER（今期予想）: -3.3
PBR: 1.9
配当利回り: —
52週レンジ: $6.65 – $36.26
業種: Healthcare / Biotechnology
上場: NASDAQ Global Select
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-09 · 更新: 2026-10-09